Display options
Cite
de Haan P, Klein HC, 't Hart BA. Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy. Front Psychiatry. 2017;8:46doi: 10.3389/fpsyt.2017.00046.
de Haan, P., Klein, H. C., & 't Hart, B. A. (2017). Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy. Frontiers in psychiatry, 846. https://doi.org/10.3389/fpsyt.2017.00046
de Haan, Peter, et al. "Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy." Frontiers in psychiatry vol. 8 (2017): 46. doi: https://doi.org/10.3389/fpsyt.2017.00046
de Haan P, Klein HC, 't Hart BA. Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy. Front Psychiatry. 2017 Apr 04;8:46. doi: 10.3389/fpsyt.2017.00046. eCollection 2017. PMID: 28421005; PMCID: PMC5378775.
Copy Download .nbib Format: NLM
Share it on

Front Psychiatry. 2017 Apr 04;8:46. doi: 10.3389/fpsyt.2017.00046. eCollection 2017.

Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy.

Frontiers in psychiatry

Peter de Haan, Hans C Klein, Bert A 't Hart

Affiliations

  1. Amarna Therapeutics B.V., Leiden, Netherlands.
  2. Department of Psychiatry and Medical Imaging Centre, University Medical Centre Groningen, Groningen, Netherlands.
  3. Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands.

PMID: 28421005 PMCID: PMC5378775 DOI: 10.3389/fpsyt.2017.00046

Abstract

Neurodegenerative and psychiatric diseases (NPDs) are today's most important group of diseases, surpassing both atherosclerotic cardiovascular disease and cancer in morbidity incidence. Although NPDs have a dramatic impact on our society because of their high incidence, mortality, and severe debilitating character, remarkably few effective interventions have become available. The current treatments, if available, comprise the lifelong intake of general immunosuppressants to delay disease progression or neurotransmitter antagonists/agonists to dampen undesired behaviors. The long-term usage of such medication, however, coincides with often severe adverse side effects. There is, therefore, an urgent need for safe and effective treatments for these diseases. Here, we discuss that many NPDs coincide with subtle chronic or flaring brain inflammation sometimes escalating with infiltrations of lymphocytes in the inflamed brain parts causing mild to severe or even lethal brain damage. Thus, NPDs show all features of autoimmune diseases. In this review, we postulate that NPDs resemble autoimmune-driven inflammatory diseases in many aspects and may belong to the same disease spectrum. Just like in autoimmune diseases, NPD symptoms basically are manifestations of a chronic self-sustaining inflammatory process with detrimental consequences for the patient. Specific inhibition of the destructive immune responses in the brain, leaving the patient's immune system intact, would be the ultimate solution to cure patients from the disease. To reach this goal, the primary targets, e.g., the primary self-antigens (pSAgs) of the patient's chronic (auto)immune response, need to be identified. For a few major NPDs, immunological studies led to the identification of the pSAgs involved in the autoimmune damage of specific brain parts. However, further research is needed to complete the list of pSAgs for all NPDs. Such immunological studies will not only provide crucial insights into NPD pathogenesis but also ultimately enable the development of a new generation of safe and effective immunotherapies for NPDs. Interventions that will dramatically improve the life expectancy and quality of life of individual patients and, moreover, will significantly reduce the health-care costs of the society in general.

Keywords: chronic inflammation; immune tolerance; neurodegenerative disease; psychiatric disease; reverse vaccine; self-antigen; viral vector

References

  1. J Hepatol. 2015 Jun;62(6):1349-56 - PubMed
  2. Psychiatrie (Stuttg). 2009 Jan 1;6(1):5-9 - PubMed
  3. J Neuroinflammation. 2013 Apr 01;10:43 - PubMed
  4. Brain Behav Immun. 2014 Nov;42:50-9 - PubMed
  5. Nat Rev Immunol. 2016 Jan;16(1):22-34 - PubMed
  6. Science. 1994 Jul 29;265(5172):648-51 - PubMed
  7. Acta Neurobiol Exp (Wars). 1999;59(1):1-8 - PubMed
  8. Vaccine. 2014 Sep 29;32(43):5681-9 - PubMed
  9. Cell Death Dis. 2013 Mar 28;4:e560 - PubMed
  10. J Psychoactive Drugs. 2012 Apr-Jun;44(2):134-43 - PubMed
  11. J Psychopharmacol. 2013 Apr;27(4):337-42 - PubMed
  12. J Neuroimmune Pharmacol. 2015 Dec;10(4):610-9 - PubMed
  13. Sci Pract Perspect. 2007 Apr;3(2):4-16 - PubMed
  14. Transl Psychiatry. 2016 Apr 12;6:e778 - PubMed
  15. Ann Neurol. 1990 Sep;28(3):365-72 - PubMed
  16. Neurosci Biobehav Rev. 2008;32(3):525-49 - PubMed
  17. Lancet. 1997 May 24;349(9064):1498-504 - PubMed
  18. Brain Behav Immun. 2012 Nov;26(8):1273-9 - PubMed
  19. Nature. 2016 Sep 1;537(7618):97-101 - PubMed
  20. Science. 1999 Jan 15;283(5400):397-401 - PubMed
  21. Front Behav Neurosci. 2014 Jun 06;8:199 - PubMed
  22. Folia Neuropathol. 2006;44(3):191-6 - PubMed
  23. Neuroscience. 2008 Mar 27;152(3):573-84 - PubMed
  24. BMC Med. 2013 Sep 12;11:200 - PubMed
  25. Front Synaptic Neurosci. 2014 Aug 13;6:17 - PubMed
  26. Curr Neurol Neurosci Rep. 2011 Jun;11(3):298-304 - PubMed
  27. J Nucl Med. 2009 Nov;50(11):1801-7 - PubMed
  28. Ann Neurol. 2010 Nov;68(5):593-601 - PubMed
  29. Nat Rev Neurol. 2011 Jan;7(1):31-40 - PubMed
  30. Nat Neurosci. 2010 May;13(5):635-41 - PubMed
  31. Nat Rev Immunol. 2011 Nov 18;11(12):807-22 - PubMed
  32. Neurobiol Aging. 2015 Jan;36(1):81-9 - PubMed
  33. Neuropathol Appl Neurobiol. 1990 Oct;16(5):401-10 - PubMed
  34. Mol Cell Neurosci. 2013 Mar;53:69-76 - PubMed
  35. Mol Immunol. 2014 Feb;57(2):93-9 - PubMed
  36. J Affect Disord. 2015 Dec 1;188:149-59 - PubMed
  37. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9938-43 - PubMed
  38. Immunology. 2010 Feb;129(2):154-69 - PubMed
  39. Br J Psychiatry Suppl. 1998;(35):26-37 - PubMed
  40. Brain. 2009 May;132(Pt 5):1236-46 - PubMed
  41. Biol Psychiatry. 1999 May 1;45(9):1085-98 - PubMed
  42. Arch Neurol. 1993 Jan;50(1):30-6 - PubMed
  43. Mol Ther. 2009 Apr;17(4):632-40 - PubMed
  44. Nat Rev Immunol. 2014 Mar;14(3):166-80 - PubMed
  45. Trends Neurosci. 2002 Jun;25(6):313-9 - PubMed
  46. Eur J Neurol. 2010 Apr;17(4):562-6 - PubMed
  47. Hum Brain Mapp. 2009 Sep;30(9):2757-65 - PubMed
  48. Brain Res Brain Res Rev. 2000 Mar;31(2-3):277-87 - PubMed
  49. Nat Neurosci. 2011 Jul 10;14(8):1033-8 - PubMed
  50. J Neuroimmunol. 2002 Oct;131(1-2):179-85 - PubMed
  51. Brain Res. 2015 Aug 18;1617:72-92 - PubMed
  52. Neuron. 2000 Nov;28(2):343-7 - PubMed
  53. Mol Ther. 2012 May;20(5):918-26 - PubMed
  54. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977-82 - PubMed
  55. Biol Psychiatry. 2005 Aug 15;58(4):297-306 - PubMed
  56. Trends Immunol. 2004 Jul;25(7):353-9 - PubMed
  57. J Neural Transplant. 1989;1(2):63-76 - PubMed
  58. Ann N Y Acad Sci. 1993 Sep 24;695:244-8 - PubMed
  59. Discov Med. 2011 May;11(60):449-58 - PubMed
  60. Hum Gene Ther. 2012 May;23(5):460-72 - PubMed
  61. Mol Neurobiol. 2011 Oct;44(2):160-5 - PubMed
  62. Nature. 1996 Feb 15;379(6566):606-12 - PubMed
  63. JAMA Psychiatry. 2015 Mar;72(3):268-75 - PubMed
  64. Cell. 1999 Aug 20;98(4):427-36 - PubMed
  65. Nat Neurosci. 2007 Sep;10(9):1116-24 - PubMed
  66. Mol Psychiatry. 2002;7(5):437-45 - PubMed
  67. Brain. 2016 Dec;139(Pt 12):3296-3309 - PubMed
  68. Nat Rev Immunol. 2015 Dec;15(12):725 - PubMed
  69. Nat Commun. 2016 Apr 04;7:11153 - PubMed
  70. Curr Protoc Immunol. 2010 Feb;Chapter 15:Unit 15.1 - PubMed
  71. Am J Psychiatry. 2016 Feb 1;173(2):174-83 - PubMed
  72. Brain Res. 1997 Feb 14;748(1-2):62-70 - PubMed
  73. Front Immunol. 2013 Sep 23;4:294 - PubMed
  74. J Clin Invest. 2008 Oct;118(10):3403-10 - PubMed
  75. Biol Psychiatry. 2005 Mar 15;57(6):667-73 - PubMed
  76. J Neurosci. 2013 Oct 16;33(42):16409-11 - PubMed
  77. Curr Opin Neurol. 2010 Apr;23(2):111-7 - PubMed
  78. J Neuroimmunol. 2012 Nov 15;252(1-2):100-5 - PubMed
  79. Eur J Pharmacol. 2003 Aug 22;476(1-2):3-16 - PubMed
  80. Synapse. 2000 Sep 1;37(3):194-204 - PubMed
  81. Ann Neurol. 1992 Oct;32(4):494-501 - PubMed
  82. J Neurochem. 2008 Apr;105(1):78-90 - PubMed
  83. Neurol Res Int. 2011;2011:497080 - PubMed
  84. Mol Psychiatry. 2000 Jul;5(4):378-88 - PubMed
  85. Neuron. 1995 Apr;14(4):755-62 - PubMed
  86. Perspect Biol Med. 1978 Autumn;22(1):104-14 - PubMed
  87. Br J Psychiatry. 2005 Oct;187:314-9 - PubMed
  88. Parkinsons Dis. 2011 Feb 21;2011:124165 - PubMed
  89. Psychother Psychosom Med Psychol. 2007 Sep-Oct;57(9-10):379-94 - PubMed
  90. Epilepsy Res. 2008 Jan;78(1):7-21 - PubMed
  91. J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):274-8 - PubMed
  92. J Psychopharmacol. 1999 Dec;13(4):337-45 - PubMed
  93. FASEB J. 2009 Nov;23(11):3659-73 - PubMed
  94. Biol Psychiatry. 2015 Jan 15;77(2):147-57 - PubMed
  95. J Clin Invest. 2009 Jan;119(1):182-92 - PubMed
  96. J Autoimmun. 2016 Dec;75:20-29 - PubMed
  97. J Neuroimmunol. 1995 Mar;57(1-2):45-53 - PubMed
  98. Lancet Neurol. 2016 Mar;15(3):317-31 - PubMed
  99. Trends Immunol. 2015 Jun;36(6):364-73 - PubMed
  100. Neurosci Biobehav Rev. 2005;29(4-5):805-28 - PubMed
  101. Semin Neurol. 2015 Jun;35(3):245-58 - PubMed
  102. Lancet Neurol. 2009 Apr;8(4):382-97 - PubMed
  103. Immunotherapy. 2011 Oct;3(10):1223-33 - PubMed
  104. J Neuroimmune Pharmacol. 2015 Dec;10(4):547-60 - PubMed
  105. J Child Psychol Psychiatry. 2006 Oct;47(10):1051-62 - PubMed
  106. Brain. 2011 Jan;134(Pt 1):110-8 - PubMed
  107. Neuroscience. 1991;40(2):297-305 - PubMed
  108. Nature. 2011 Jul 06;475(7354):27-30 - PubMed
  109. Neurology. 1988 Aug;38(8):1285-91 - PubMed
  110. Ann Neurol. 2002 Mar;51(3):311-8 - PubMed
  111. Am J Alzheimers Dis Other Demen. 2015 May;30(3):225-7 - PubMed
  112. Front Cell Neurosci. 2013 Nov 08;7:195 - PubMed
  113. Cell. 2010 Mar 19;140(6):871-82 - PubMed
  114. Hum Vaccin Immunother. 2012 Jun;8(6):834-7 - PubMed
  115. Nature. 2005 Jun 2;435(7042):584-9 - PubMed
  116. Nat Rev Immunol. 2016 Jul;16(7):407-20 - PubMed
  117. Nature. 1999 Jul 22;400(6742):371-5 - PubMed
  118. Clin Dev Immunol. 2013;2013:345092 - PubMed
  119. J Neuropathol Exp Neurol. 2007 Apr;66(4):295-304 - PubMed
  120. Am J Pathol. 1992 Mar;140(3):691-707 - PubMed
  121. Psychiatry Clin Neurosci. 2012 Apr;66(3):220-6 - PubMed
  122. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:71-91 - PubMed
  123. Neuropsychopharmacology. 2014 Mar;39(4):831-40 - PubMed
  124. PLoS One. 2013 Dec 18;8(12):e83271 - PubMed
  125. Annu Rev Immunol. 2014;32:257-81 - PubMed
  126. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1982-7 - PubMed
  127. Ann Neurol. 1989 Sep;26(3):368-76 - PubMed
  128. J Neurosci. 2012 Nov 28;32(48):17365-72 - PubMed
  129. Neuron. 2014 Jan 8;81(1):77-90 - PubMed
  130. PLoS One. 2014 Dec 16;9(12):e115009 - PubMed
  131. Adv Protein Chem Struct Biol. 2012;88:1-25 - PubMed
  132. Lancet Neurol. 2016 Apr;15(4):391-404 - PubMed
  133. J Pharmacol Exp Ther. 2016 May;357(2):264-72 - PubMed
  134. Mol Ther Methods Clin Dev. 2014 Apr 30;1:14013 - PubMed
  135. J Neurosci. 2014 Jun 11;34(24):8210-8 - PubMed
  136. Mol Psychiatry. 2013 Dec;18(12):1265-72 - PubMed
  137. Neurobiol Dis. 1999 Oct;6(5):392-405 - PubMed
  138. J Neuroimmunol. 2015 Jan 15;278:212-22 - PubMed
  139. Am J Psychiatry. 2016 Jan;173(1):44-52 - PubMed
  140. Behav Brain Funct. 2012 Nov 28;8:54 - PubMed
  141. Synapse. 2008 Jul;62(7):481-6 - PubMed
  142. Immunol Rev. 2012 Sep;249(1):158-75 - PubMed
  143. Neuropsychopharmacology. 2009 Nov;34(12):2489-96 - PubMed

Publication Types